Fig. 1 · Structure

Documents & Downloads

A-770041

Cat. No. A11288 CAS 869748-10-7

Lck inhibitor

A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

A-770041 Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of A-770041 from 3 published references. In vitro models include U-2OSMR; KHOSR2. In vivo models include eight-week-old male C57BL/6 mice.

A-770041 In Vitro Studies

In U-2OSMR osteosarcoma MDR cells, A-770041 at 0.3 μM and 1 μM for 48 hours inhibited Src and Lck activation and expression. In KHOSR2 cells, A-770041 at concentrations up to 1 μM for 48 hours did not alter Pgp protein expression. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Src and Lck activation and expression in osteosarcoma cells

Cell-based study · U-2OSMR [1]

In U-2OSMR osteosarcoma MDR cells, A-770041 at 0.3 μM and 1 μM for 48 hours inhibited Src and Lck activation and expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Src and Lck activation and expressionReported result 0.3 μM, 1 μM for 48 hours: A-770041 inhibits both Src and Lck activation and expression in osteosarcoma MDR cells.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.3 μM, 1 μM
Exposure duration
48 hours
Method
in regular RPMI1640 medium
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: A-770041

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effect of A-770041 on the expression and activation of Src, Lck (S88, S89, S91); Results > A-770041 induced apoptosis contributes to the reversal of Pgp-mediated paclitaxel and doxorubicin resistance (S96)

Src and Lck activation and expression: Src and Lck activation and expression; comparator: 0 μM — Results > Effect of A-770041 on the expression and activation of Src, Lck (S88, S89); Results > A-770041 induced apoptosis contributes to the reversal of Pgp-mediated paclitaxel and doxorubicin resistance (S96)

Pgp protein expression in KHOSR2 cells

Cell-based study · KHOSR2 [1]

In KHOSR2 cells, incubation with A-770041 at concentrations up to 1 μM for 48 hours did not alter Pgp protein expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
expression of Pgp protein levelsReported result After incubating the cells with A-770041 at concentrations up to 1 μM for 48 hours, A-770041 did not alter the expression of Pgp protein levels.[1]

Literature-Reported Treatment Conditions

Treatment concentration
up to 1 μM
Exposure duration
48 hours
Reported limits
Not stated in the sentences used: route, vehicle, control.
Methods and source locations

Compound reported in the paper: A-770041

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > A-770041 induced apoptosis contributes to the reversal of Pgp-mediated paclitaxel and doxorubicin resistance (S103, S104)

expression of Pgp protein levels: expression of Pgp protein levels — Results > A-770041 induced apoptosis contributes to the reversal of Pgp-mediated paclitaxel and doxorubicin resistance (S104)

A-770041 In Vivo Studies

Male C57BL/6 mice received the compound at 5 mg/kg/d by gavage on days 0 to 21 (full treatment). Ashcroft fibrotic scores in the early-phase and full-treatment groups were significantly lower than in mice treated with BLM alone. In CE-exposed allergic mice, intranasal treatment with the study compound before CE challenge significantly reduced allergic airway inflammation, reflected by lower total leukocyte, eosinophil, and lymphocyte counts in BAL compared with the CE-administered control group. [2,3]

Gavage treatment and Ashcroft scores in mice

Animal study · Eight-week-old male C57BL/6 mice [2]

Male C57BL/6 mice received the compound at 5 mg/kg/d by gavage on days 0 to 21 (full treatment). Ashcroft fibrotic scores in the early-phase and full-treatment groups were significantly lower than in mice treated with BLM alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ashcroft scoreReported result the Ashcroft fibrotic score in the early-phase and full-treatment groups was significantly lower than in those treated with BLM alone[2]

Conditions shared by the study groups

Route
by gavage
Treatment course
days 0 to 21 (full treatment)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
A-770041 5 mg/kg/dBLM alonethe Ashcroft fibrotic score in the early-phase and full-treatment groups was significantly lower than in those treated with BLM alone[2]
A-770041 5 mg/kg/d
Model: Eight-week-old male C57BL/6 mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: A-770041

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Mice and agents (S2); Materials and methods > BLM-induced lung fibrosis in mice (S12); Results > A-77041 attenuates BLM-induced lung fibrosis in mice (S33, S37); Fig 2 legend (S70, S71, S74, S75)

Ashcroft score: Ashcroft score; comparator: BLM alone — Results > A-77041 attenuates BLM-induced lung fibrosis in mice (S37); Fig 2 legend (S74)

A-770041 5 mg/kg/d · Results > A-77041 attenuates BLM-induced lung fibrosis in mice (S33, S37); Fig 2 legend (S70, S71)

Intranasal pretreatment reduced airway inflammation in CE-exposed mice

Animal study · C57BL/6 mice; CE-exposed allergic mice; n = 6–8/group [3]

In CE-exposed allergic mice, intranasal treatment with the study compound before CE challenge significantly reduced allergic airway inflammation, reflected by lower total leukocyte, eosinophil, and lymphocyte counts in BAL compared with the CE-administered control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total leukocytes count in BALReported result In CE-exposed mice, at a dose of 10 mg/kg for 5 consecutive days, 30 min before CE challenge (day 11–15): significant reduction in allergic airway inflammation as displayed by total leukocyte count, eosinophilic count, and lymphocytic count in BAL.[3]

Conditions shared by the study groups

Route
i.n.
Treatment course
for 5 consecutive days, 30 min before CE challenge (day 11–15)
Vehicle
dimethylsulfoxide
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
A-770041 10 mg/kgGroup C: CE-administered group (CE)In CE-exposed mice, at a dose of 10 mg/kg for 5 consecutive days, 30 min before CE challenge (day 11–15): significant reduction in allergic airway inflammation as displayed by total leukocyte count, eosinophilic count, and lymphocytic count in BAL.[3]
A-770041 10 mg/kg
Model: C57BL/6 mice; CE-exposed allergic mice; n = 6–8/group
Methods and source locations

Compound reported in the paper: A-770041

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Animals (S1); 2. Materials and Methods > 2.2. Development of Cockroach Extract (CE)-Induced Allergic Inflammation in Mice (S6, S7); 2. Materials and Methods > 2.3. Experimental Groups (S9, S10, S13, S14); 3. Results > 3.2. Inhibition of LCK Signaling Causes Reduction in Airway Inflammation in CE-Induced Allergic Model of Asthma (S53, S54); Figure 2 legend (S88, S89, S90); Figure 8 legend (S105)

Total leukocytes count in BAL: Total leukocytes count in BAL; comparator: Group C: CE-administered group (CE) — 2. Materials and Methods > 2.3. Experimental Groups (S10); 3. Results > 3.2. Inhibition of LCK Signaling Causes Reduction in Airway Inflammation in CE-Induced Allergic Model of Asthma (S53, S54); Figure 2 legend (S89)

A-770041 10 mg/kg · 2. Materials and Methods > 2.3. Experimental Groups (S9, S10, S14); 3. Results > 3.2. Inhibition of LCK Signaling Causes Reduction in Airway Inflammation in CE-Induced Allergic Model of Asthma (S53, S54)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 869748-10-7
Applications Lck inhibitor
Formula C34H39N9O3
Molecular Weight 621.75
SMILES
CC(=O)N1CCN(CC1)C2CCC(CC2)N3C4=C(C(=N3)C5=CC(=C(C=C5)NC(=O)C6=CC7=CC=CC=C7N6C)OC)C(=NC=N4)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

A-770041 Research References

  1. [1] Duan Z, Zhang J, Ye S, et al. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer (2014). PMID: 25236161 DOI: 10.1186/1471-2407-14-681 Source material
  2. [2] Kagawa K, Sato S, Koyama K, et al. The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-β production in regulatory T-cells. PLoS One (2022). PMID: 36301948 DOI: 10.1371/journal.pone.0275987 Source material
  3. [3] Alqarni SA, Bineid A, Ahmad SF, et al. Blockade of Tyrosine Kinase, LCK Leads to Reduction in Airway Inflammation through Regulation of Pulmonary Th2/Treg Balance and Oxidative Stress in Cockroach Extract-Induced Mouse Model of Allergic Asthma. Metabolites (2022). PMID: 36144198 DOI: 10.3390/metabo12090793 Source material

Added to your cart

View Cart Checkout
Loading...